Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. The Company's research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s capacity for cellular growth and repair. The Company’s lead product candidate, luspatercept, is being evaluated in two Phase 3 studies in a global partnership with Celgene to treat chronic, sometimes debilitating anemias in myelodysplastic syndromes (MDS) and beta-thalassemia. Acceleron is also advancing clinical programs in neuromuscular disorders and cancer, and preclinical research in fibrotic and other diseases.

Type
Public
HQ
Cambridge, US
Founded
2003
Size (employees)
121 (est)
Acceleron Pharma was founded in 2003 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Acceleron Pharma

Habib Dable

Habib Dable

President and Chief Executive Officer
Kevin McLaughlin

Kevin McLaughlin

CFO
Steven Ertel

Steven Ertel

COO
Matthew Sherman

Matthew Sherman

Chief Medical Officer
Ravi Kumar

Ravi Kumar

Chief Scientific Officer
John Quisel

John Quisel

SVP, Business Development and General Councel
Show more

Acceleron Pharma Office Locations

Acceleron Pharma has an office in Cambridge
Cambridge, US (HQ)
128 Sidney Street
Show all (1)
Report incorrect company information

Acceleron Pharma Financials and Metrics

Acceleron Pharma Financials

Acceleron Pharma's revenue was reported to be $13.48 m in FY, 2017
USD

Revenue (Q1, 2018)

3.2 m

Net income (Q1, 2018)

(26.2 m)

EBIT (Q1, 2018)

(27.6 m)

Market capitalization (22-Jun-2018)

1.7 b

Closing share price (22-Jun-2018)

37.4

Cash (31-Mar-2018)

69.7 m
Acceleron Pharma's current market capitalization is $1.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

57.2 m14.6 m18.1 m27.8 m13.5 m

Revenue growth, %

(74%)24%53%

General and administrative expense

25.3 m33.7 m

R&D expense

68.6 m89.7 m
Quarterly
USDQ1, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

3.3 m5.7 m4.2 m18.2 m3.2 m3 m3.7 m3.1 b3.2 m

General and administrative expense

3.8 m4.7 m5.4 m5.9 m6.7 m6.4 m7.8 m11.4 b7.4 m

R&D expense

11.8 m14.2 m13.3 m16.2 m16.1 m17.1 m21.7 m21.6 b23.4 m

Operating expense total

15.5 m18.8 m18.8 m22.2 m22.9 m23.5 m29.6 m33 b30.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

113.2 m176.5 m27.8 m21 m100.2 m

Accounts Receivable

11.5 m

Inventories

2.2 m2.5 m2.5 m3.9 m

Current Assets

119 m182.3 m110.9 m146.8 m285.2 m
Quarterly
USDQ1, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

214.1 m43.4 m63.7 m37 m31 m33.2 m30.7 m69.7 m

Current Assets

218.5 m122.4 m170.7 m127 m145 m149 m148.4 m300.3 m

PP&E

3.7 m2.9 m3.7 m4.2 m4.2 m7.1 m7.2 m7 m

Total Assets

223 m158.4 m289.6 m274.2 m262.9 m229.1 m208.5 m370 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(21.9 m)(51.3 m)(63.9 m)(57 m)(108.5 m)

Depreciation and Amortization

915 k1.1 m1.2 m1.7 m2.8 m

Inventories

(823 k)(255 k)7 k(1.4 m)

Accounts Payable

(53 k)(161 k)151 k644 k(504 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(9.1 m)(10.4 m)(11.9 m)5.1 m(22 m)(25.4 m)(26.2 m)

Depreciation and Amortization

904 k

Accounts Payable

891 k2.6 m3.3 m1.6 m1.8 m2.6 m1.2 m566 k2.1 m911 k591 k

Cash From Operating Activities

(23.4 m)
USDY, 2018

Financial Leverage

1 x
Show all financial metrics

Acceleron Pharma Operating Metrics

FY, 2015FY, 2016

Phase III Trials Products

2 2
Show all operating metrics
Report incorrect company information

Acceleron Pharma Online and Social Media Presence

Embed Graph
Report incorrect company information

Acceleron Pharma News and Updates

Report incorrect company information